Joseph Woodard
Förmögenhet: 4 142 $ per 2026-08-31
Förmögenhet: 4 142 $ per 2026-08-31
Joseph Paul Woodard formerly worked at Bellicum Pharmaceuticals, Inc., as Senior Vice President-Clinical & Medical Affairs in 2019, Imugene Ltd., as Chief Medical Officer from 2023 to 2025, and Immune-Onc Therapeutics, Inc., as Chief Medical Officer & Senior Vice President.
Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and doctorate degree from UNC School of Medicine.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IMUGENE LTD 0,02 % | 2025-06-30 | 85 007 ( 0,02 % ) | 4 142 $ | 2026-08-31 |
| Företag | Position | Slut |
|---|---|---|
| IMUGENE LIMITED | Teknisk/Vetenskaplig/F&U Direktör | 2025-05-30 |
| BELLICUM PHARMACEUTICALS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2019-11-01 |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Teknisk/Vetenskaplig/F&U Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Imugene Ltd.
Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UNC School of Medicine
UNC School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån